Steady-state kinetic analyses revealed that the methylation reaction of the human DNA (cytosine-5) methyltransferase 1 (DNMT1) is repressed by the N-terminal domain comprising the first 501 amino acids, and that repression is relieved when methylated DNA binds to this region. DNMT1 lacking the first 501 amino acids retains its preference for hemimethylated DNA. The methylation reaction proceeds by a sequential mechanism, and either substrate (S-adenosyl-L-methionine and unmethylated DNA) may be the first to bind to the active site. However, initial binding of S-adenosyl-L-methionine is preferred. The binding affinities of DNA for both the regulatory and the catalytic sites increase in the presence of methylated CpG dinucleotides and vary considerably (more than one hundred times) according to DNA sequence. DNA topology strongly influences the reaction rates, which increased with increasing negative superhelical tension. These kinetic data are consistent with the role of DNMT1 in maintaining the methylation patterns throughout development and suggest that the enzyme may be involved in the etiology of fragile X, a syndrome characterized by de novo methylation of a greatly expanded CGG⅐CCG triplet repeat sequence.The mammalian genome is epigenetically modified by the transfer of methyl groups from S-adenosyl-L-methionine (AdoMet) 1 to acceptor bases in double-stranded DNA, mostly at the carbon 5 of cytosine when the base is part of a CG dinucleotide (1). Several DNA methyltransferases (Dnmt) have been identified, including Dnmt1 (2), Dnmt2 (3), Dnmt3A, Dnmt3B (4), a splice variant of Dnmt1 (Dnmt1b) (5), and an oocytespecific isoform of Dnmt1 that lacks the first 118 N-terminal amino acids (6). Targeted mutations of Dnmt1 (7), Dnmt3A, and Dnmt3B genes are recessive lethals (8) in mice attesting to their essential role in development. In humans, mutations in the DNMT3B gene have been associated with the (immunodeficiency, centromere instability, and facial abnormalities syndrome (ICF syndrome) (9), a recessive disorder characterized biochemically by hypomethylation of satellite 2 and 3 DNA from the juxtacentromeric heterochromatin of chromosomes 1 and 16 (10 -12) as well as other common non-satellite repeats (13).Genetic studies suggest that Dnmt1 and Dnmt3 carry out two types of modifications as follows: both Dnmt3A and -B establish patterns of methylation early in embryogenesis by de novo methylation of cytosine residues, whereas Dnmt1 maintains such patterns throughout life by copying them onto newly synthesized DNA (4,14). Methylation studies in vitro do not reveal such distinction of functions. In fact, whereas kinetic determinations show that Dnmt1 utilizes hemimethylated DNA 5-10-fold better than unmethylated DNA (15-19), they also show that this enzyme methylates unmethylated DNA more efficiently than Dnmt3A and Dnmt3B (4). Therefore, it is unclear whether the de novo activity of Dnmt1 is repressed in vivo.Most cases of fragile X syndrome, a relatively frequent (1: 4000 births) hereditary neurological disea...